Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SNOA logo SNOA
Upturn stock ratingUpturn stock rating
SNOA logo

Sonoma Pharmaceuticals Inc (SNOA)

Upturn stock ratingUpturn stock rating
$4.56
Last Close (24-hour delay)
Profit since last BUY-12.81%
upturn advisory
Consider higher Upturn Star rating
BUY since 8 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: SNOA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $14.8

1 Year Target Price $14.8

Analysts Price Target For last 52 week
$14.8 Target price
52w Low $1.75
Current$4.56
52w High $6.92

Analysis of Past Performance

Type Stock
Historic Profit -25.93%
Avg. Invested days 31
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 7.49M USD
Price to earnings Ratio -
1Y Target Price 14.8
Price to earnings Ratio -
1Y Target Price 14.8
Volume (30-day avg) 1
Beta 1.26
52 Weeks Range 1.75 - 6.92
Updated Date 08/29/2025
52 Weeks Range 1.75 - 6.92
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.21

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-06
When After Market
Estimate -0.51
Actual -0.4793

Profitability

Profit Margin -23.84%
Operating Margin (TTM) -27.27%

Management Effectiveness

Return on Assets (TTM) -16.06%
Return on Equity (TTM) -78.73%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4563288
Price to Sales(TTM) 0.5
Enterprise Value 4563288
Price to Sales(TTM) 0.5
Enterprise Value to Revenue 0.31
Enterprise Value to EBITDA -0.17
Shares Outstanding 1643260
Shares Floating 1622330
Shares Outstanding 1643260
Shares Floating 1622330
Percent Insiders 1.23
Percent Institutions 6.31

ai summary icon Upturn AI SWOT

Sonoma Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Sonoma Pharmaceuticals, Inc. (formerly Oculus Innovative Sciences) was founded in 2005. It focuses on developing and marketing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, eye care, and dermatology. The company has evolved from its initial focus on disinfection to a broader range of therapeutic applications.

business area logo Core Business Areas

  • Human Healthcare: Development, manufacturing, and marketing of prescription and over-the-counter products for advanced tissue care, primarily using Microcyn Technology (stabilized HOCl). This includes products for wound care, scar management, eye care, and dermatology.
  • Animal Healthcare: Products based on Microcyn Technology for use in the veterinary market, treating wounds and other skin conditions in animals.
  • International Partnerships: Partnering with distributors and companies to sell Sonoma's products internationally, expanding market reach beyond North America.

leadership logo Leadership and Structure

The leadership team includes Amy Trombly (CEO), James Schutz (CFO), and other executives managing different areas of the business. The organizational structure is typical for a publicly traded pharmaceutical company with departments for R&D, manufacturing, sales, and marketing.

Top Products and Market Share

overview logo Key Offerings

  • Microcyn Technology: Sonoma's core technology platform is based on stabilized hypochlorous acid (HOCl). It is used in various products for wound care, scar management, eye care, and dermatology. Market share data specifically for Microcyn is not readily available. Competitors in wound care include companies like Smith & Nephew (SNN), Mu00f6lnlycke Health Care, and 3M (MMM). Competitors in scar management include companies like Merz Pharma and Cynosure (CCXX).
  • OCuSOFT Products: Sonoma distributes OCuSOFT products. Market share is not readily available. Competitors in this space are Johnson & Johnson (JNJ) and Alcon (ALC).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive, with continuous innovation and development of new therapies. Specific to wound care, scar management, and dermatology, the markets are driven by aging populations, increased incidence of chronic diseases, and rising demand for cosmetic procedures.

Positioning

Sonoma Pharmaceuticals is a niche player in the pharmaceutical industry, focusing on HOCl technology. Its competitive advantage lies in its patented technology and its efficacy in wound care and other applications.

Total Addressable Market (TAM)

The global wound care market is expected to reach hundreds of billions of USD. Sonoma's TAM is smaller, focusing on specific segments within this market. Their positioning centers on specialized areas, allowing them to capture a piece of a larger market.

Upturn SWOT Analysis

Strengths

  • Proprietary Microcyn Technology
  • Established distribution network
  • Multiple product applications (wound care, eye care, dermatology)
  • Regulatory approvals for key products

Weaknesses

  • Limited financial resources compared to larger competitors
  • Dependence on key partnerships for distribution
  • Smaller market share in highly competitive markets
  • Limited brand recognition compared to established players

Opportunities

  • Expansion into new markets (geographically or product categories)
  • Increased adoption of HOCl-based therapies
  • Strategic partnerships with larger pharmaceutical companies
  • Development of new formulations and delivery systems for Microcyn Technology

Threats

  • Competition from established players with greater resources
  • Regulatory changes and reimbursement pressures
  • Patent expiration and generic competition
  • Potential for adverse events or safety concerns related to products

Competitors and Market Share

competitor logo Key Competitors

  • Smith & Nephew (SNN)
  • Mu00f6lnlycke Health Care
  • 3M (MMM)
  • Johnson & Johnson (JNJ)
  • Alcon (ALC)

Competitive Landscape

Sonoma Pharmaceuticals faces strong competition from larger, more established players. Its advantages lie in its proprietary technology and focus on niche markets, but its weaknesses include limited resources and brand recognition.

Growth Trajectory and Initiatives

Historical Growth: The company's historical growth has been inconsistent, with periods of rapid growth followed by periods of stagnation. This is attributed to the company's inability to maintain its market presence due to large competitors and financial constraints.

Future Projections: Future projections are difficult to make without access to the latest information.

Recent Initiatives: Without sufficient financial data, it is not possible to provide the most recent activities.

Summary

Sonoma Pharmaceuticals is a small player in a competitive pharmaceutical industry. Its Microcyn Technology offers potential advantages, but the company faces financial challenges and strong competition. Future success depends on its ability to expand into new markets and form strategic partnerships. The company is currently delisted, which makes it difficult to assess their viability and future.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • Previous financial reports (last available)
  • Industry reports (wound care, dermatology)
  • Market research reports
  • Various news and press releases

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Market share data is approximate and based on available information. Investing in Sonoma Pharmaceuticals (SNOA) is highly speculative, considering that it is currently delisted.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Sonoma Pharmaceuticals Inc

Exchange NASDAQ
Headquaters Boulder, CO, United States
IPO Launch date 2007-01-25
CEO, President & Director Ms. Amy M. Trombly Esq., J.D.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 8
Full time employees 8

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.